ADRX-0706

ADRX-0706 is a clinical-stage antibody-drug conjugate (ADC) developed by Adcentrx Therapeutics for the treatment of advanced solid tumors, with a primary focus on cervical cancer. The drug consists of a novel fully human IgG1 monoclonal antibody that targets nectin-4, a cell surface adhesion protein highly expressed in various solid tumors and associated with poor prognosis. This antibody is linked via Adcentrx's proprietary i-Conjugation technology to AP052, a novel tubulin inhibitor payload, using a cleavable linker and stable conjugation chemistry. The ADC has a drug-antibody ratio (DAR) of 8, which allows for efficient delivery of the cytotoxic payload to tumor cells expressing nectin-4. Preclinical studies have demonstrated favorable pharmacokinetic and safety profiles as well as significant efficacy across multiple tumor types. In early clinical trials, ADRX-0706 has shown preliminary efficacy signals and differentiated safety characteristics—including low rates of peripheral neuropathy—supporting its potential as a best-in-class therapy for patients with limited treatment options[2][4][5][7][8].

Other names

anti-nectin-4 antibody-drug conjugate ADRX-0706anti-nectin4 antibody-drug conjugate ADRX-0706anti-nectin 4 antibody-drug conjugate ADRX-0706